Q2 2024 EPS Estimates for Zoetis Inc. Decreased by Analyst (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Investment analysts at William Blair dropped their Q2 2024 earnings per share estimates for Zoetis in a research report issued to clients and investors on Thursday, May 2nd. William Blair analyst B. Vazquez now forecasts that the company will post earnings per share of $1.46 for the quarter, down from their prior forecast of $1.49. The consensus estimate for Zoetis’ current full-year earnings is $5.77 per share. William Blair also issued estimates for Zoetis’ Q3 2024 earnings at $1.48 EPS, Q4 2024 earnings at $1.43 EPS, FY2024 earnings at $5.76 EPS, Q1 2025 earnings at $1.53 EPS, Q2 2025 earnings at $1.64 EPS, Q3 2025 earnings at $1.66 EPS, Q4 2025 earnings at $1.61 EPS and FY2025 earnings at $6.43 EPS.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.04. Zoetis had a return on equity of 50.74% and a net margin of 27.38%. The firm had revenue of $2.19 billion during the quarter, compared to analysts’ expectations of $2.14 billion. During the same quarter in the previous year, the business earned $1.31 earnings per share. The firm’s revenue was up 9.5% compared to the same quarter last year.

A number of other brokerages have also recently weighed in on ZTS. Barclays reduced their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. Stifel Nicolaus decreased their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Finally, The Goldman Sachs Group lifted their target price on shares of Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $216.13.

Zoetis Trading Down 0.1 %

Shares of Zoetis stock opened at $167.07 on Monday. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The company has a fifty day simple moving average of $168.88 and a 200-day simple moving average of $178.93. The stock has a market cap of $76.41 billion, a price-to-earnings ratio of 32.19, a PEG ratio of 2.61 and a beta of 0.86. Zoetis has a 12-month low of $144.80 and a 12-month high of $201.92.

Hedge Funds Weigh In On Zoetis

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Hohimer Wealth Management LLC increased its holdings in shares of Zoetis by 1.2% during the fourth quarter. Hohimer Wealth Management LLC now owns 4,386 shares of the company’s stock valued at $866,000 after purchasing an additional 52 shares during the period. Forum Financial Management LP raised its position in shares of Zoetis by 0.8% during the 4th quarter. Forum Financial Management LP now owns 7,386 shares of the company’s stock worth $1,458,000 after buying an additional 56 shares in the last quarter. Angeles Wealth Management LLC raised its position in shares of Zoetis by 3.5% during the 4th quarter. Angeles Wealth Management LLC now owns 1,640 shares of the company’s stock worth $324,000 after buying an additional 56 shares in the last quarter. Prossimo Advisors LLC lifted its stake in shares of Zoetis by 1.7% in the 4th quarter. Prossimo Advisors LLC now owns 3,498 shares of the company’s stock worth $690,000 after acquiring an additional 57 shares during the period. Finally, River Street Advisors LLC boosted its holdings in shares of Zoetis by 3.4% in the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock valued at $347,000 after acquiring an additional 58 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction on Monday, March 18th. The stock was sold at an average price of $173.33, for a total value of $159,983.59. Following the completion of the transaction, the executive vice president now directly owns 15,723 shares in the company, valued at approximately $2,725,267.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold a total of 2,209 shares of company stock valued at $371,293 over the last 90 days. Insiders own 0.16% of the company’s stock.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.03%. Zoetis’s dividend payout ratio (DPR) is presently 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.